PMID- 31376622
OWN - NLM
STAT- MEDLINE
DCOM- 20200214
LR  - 20200214
IS  - 1878-1705 (Electronic)
IS  - 1567-5769 (Linking)
VI  - 75
DP  - 2019 Oct
TI  - Myrothecine A modulates the proliferation of HCC cells and the maturation of 
      dendritic cells through downregulating miR-221.
PG  - 105783
LID - S1567-5769(19)30161-4 [pii]
LID - 10.1016/j.intimp.2019.105783 [doi]
AB  - Myrothecine A, characterized from the extracts of myrothecium roridum strain 
      IFB-E012, isolated as endophytic fungi found in the traditional Chinese medicinal 
      plant Artemisia annua. Here we investigated its roles on anti-tumor and immune 
      regulation in vitro. Dendritic cells (DCs) are the most potent antigen presenting 
      cells in immune responses. Recent studies have indicated that miRNAs are 
      indispensable in regulating the development, differentiation, maturation and 
      function of DC. MiR-221, acted as an oncogene, is an important regulator in 
      cancer development by binding to 3' untranslated regions (3' UTR) of target mRNA. 
      Here, we investigated whether myrothecine A could inhibit cell proliferation in 
      hepatocellular carcinoma (HCC) cell line SMMC-7721 by regulating miR-221. The HCC 
      cells were treated with myrothecine A at different concentration, and the cell 
      growth ability was measured by MTT assay. Then we observed whether myrothecine A 
      could affect the maturation of DC by regulating miR-221. The HCC cell line was 
      co-cultured with immature DC from mice bone marrow, and the levels of CD86 and 
      CD40 was detected by FCM. Our results showed that myrothecine A could rescue 
      miR-221-induced cell proliferation and influence the protein level of p27 by 
      inhibiting the expression of miR-221. In addition, myrothecine A could enhance 
      the expression of CD86 and CD40 by reversing the function of miR-221. Therefore, 
      myrothecine A may be acted as an anti-tumor drug to promote the maturation of DC 
      in the microenvironment of hepatocellular carcinoma.
CI  - Copyright (c) 2019. Published by Elsevier B.V.
FAU - Fu, Yi
AU  - Fu Y
AD  - Department of Human Anatomy, Histology and Embryology, School of Biology and 
      Basic Medical Sciences, Soochow University, Suzhou 215007, China. Electronic 
      address: yfu@suda.edu.cn.
FAU - Li, Fengxia
AU  - Li F
AD  - School of Medicine, Yangzhou University, Yangzhou 225001, China.
FAU - Zhang, Ping
AU  - Zhang P
AD  - Institute of Hand Surgery, Ruihua Affiliated Hospital of Soochow University, 
      Suzhou 215007, China.
FAU - Liu, Mingyan
AU  - Liu M
AD  - School of Medicine, Yangzhou University, Yangzhou 225001, China.
FAU - Qian, Li
AU  - Qian L
AD  - School of Medicine, Yangzhou University, Yangzhou 225001, China.
FAU - Lv, Fengwei
AU  - Lv F
AD  - School of Medicine, Yangzhou University, Yangzhou 225001, China.
FAU - Cheng, Wenting
AU  - Cheng W
AD  - School of Medicine, Yangzhou University, Yangzhou 225001, China.
FAU - Hou, Ruixing
AU  - Hou R
AD  - Institute of Hand Surgery, Ruihua Affiliated Hospital of Soochow University, 
      Suzhou 215007, China.
LA  - eng
PT  - Journal Article
DEP - 20190731
PL  - Netherlands
TA  - Int Immunopharmacol
JT  - International immunopharmacology
JID - 100965259
RN  - 0 (Antineoplastic Agents)
RN  - 0 (MIRN221 microRNA, human)
RN  - 0 (MicroRNAs)
RN  - 0 (Trichothecenes)
RN  - 0 (myrothecin A)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/*pharmacology
MH  - Carcinoma, Hepatocellular/drug therapy/genetics
MH  - Cell Differentiation/drug effects
MH  - Cell Line, Tumor
MH  - Cell Proliferation/drug effects
MH  - Dendritic Cells/*drug effects/physiology
MH  - Down-Regulation
MH  - Humans
MH  - Liver Neoplasms/drug therapy/genetics
MH  - Mice
MH  - *MicroRNAs
MH  - Trichothecenes/*pharmacology
OTO - NOTNLM
OT  - Cell proliferation
OT  - DC
OT  - Hepatocellular carcinoma
OT  - Myrothecine A
OT  - miR-221
EDAT- 2019/08/04 06:00
MHDA- 2020/02/15 06:00
CRDT- 2019/08/04 06:00
PHST- 2019/01/25 00:00 [received]
PHST- 2019/07/24 00:00 [revised]
PHST- 2019/07/24 00:00 [accepted]
PHST- 2019/08/04 06:00 [pubmed]
PHST- 2020/02/15 06:00 [medline]
PHST- 2019/08/04 06:00 [entrez]
AID - S1567-5769(19)30161-4 [pii]
AID - 10.1016/j.intimp.2019.105783 [doi]
PST - ppublish
SO  - Int Immunopharmacol. 2019 Oct;75:105783. doi: 10.1016/j.intimp.2019.105783. Epub 
      2019 Jul 31.